Chapter 1 : HIV-1-Associated Neurocognitive Disorders in the HAART Era

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in

HIV-1-Associated Neurocognitive Disorders in the HAART Era, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555815691/9781555813697_Chap01-1.gif /docserver/preview/fulltext/10.1128/9781555815691/9781555813697_Chap01-2.gif


Early in the HIV/AIDS epidemic, the deleterious consequences of HIV-1 infection in the central and peripheral nervous system were described. They were considered to be due to severe immunosuppression, and encephalitis was considered predominantly attributable to concomitant cytomegalovirus (CMV) infection. Antiretroviral agents (ARVs) was further noted that patients with HIV-1-associated neurocognitive disorders would initially improve but later progress despite the continued use of zidovudine (ZDV). In December 1995, the highly active antiretroviral therapy (HAART) era began when the protease inhibitors (PIs) were introduced into practice with the FDA approval of saquinavir. A number of changes have occurred across the spectrum of HIV-1-associated neurocognitive disorders since the introduction of HAART. The incidence of HIV-1-associated dementia (HAD) is widely reported to have decreased following the introduction of HAART; however, the incidence of HIV-1 encephalopathy (as defined neuropathologically) appears to have increased, although interestingly, both the neuropathological and the clinical aspects of the syndrome seem to be less severe than those observed in the pre-HAART era. In addition to the above-mentioned changes in clinical manifestations of HIV-1-associated neurocognitive disorders, their underlying pathophysiology has also evolved. Aside from the original focus on virologic (pathogen), inflammatory/immunologic (host response), and comorbid infection factors, there are now three additional categories of pathogenic factors that demand attention. These are the vascular, medication toxicity, and genetic factors. Molecular investigations of multidrug resistance (MDR) resulted in the isolation and characterization of genes coding for several associated proteins, including P-glycoprotein and the MDR-associated protein MRP1.

Citation: Goodkin K, Aronow A, Baldwin G, Molina R, Zheng W, Hardy W. 2009. HIV-1-Associated Neurocognitive Disorders in the HAART Era, p 3-27. In Goodkin K, Shapshak P, Verma A (ed), The Spectrum of Neuro-AIDS Disorders. ASM Press, Washington, DC. doi: 10.1128/9781555815691.ch1
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


Image of FIGURE 1.

Steps at which ARVs interfere with the replication cycle of HIV-1. Regarding the structure of HIV-1, the glycoprotein coat is comprised of two portions, the outer envelope, gp120, and the transmembrane portion, gp41. The matrix protein, p17, bridges the glycoprotein coat, with the cone-shaped structure forming the viral capsid protein, p24. The viral genomic RNA, the processed nucleocapsid (p7/p9), Pol proteins, the reverse transcriptase enzyme, and the integrase enzyme are located within the capsid core. The life cycle of HIV-1 is depicted from left to right. The first FDA-approved ARVs were the nRTIs, which interfere with the step of reverse transcription, in which the RNA of HIV-1 is reverse transcribed into a complementary DNA copy. Soon afterward, members of two new ARV classes were FDA approved, the NNRTIs and the PIs. The NNRTIs act at the same point as the nRTIs but at a different site of the reverse transcriptase enzyme. The PIs, however, were the first ARVs approved to work at a different step in the viral replicatory cycle, which is a late step in which posttranslational modification of viral preproteins into active proteins occurs prior to virus assembly. Subsequently, the first of the fusion/entry inhibitors (including the CCR5 antagonists) was FDA approved. These drugs act by inhibiting the process of fusion between the viral envelope and the host cell membrane or in the immediately subsequent process of virus entry into the cell. Most recently, another class of ARVs was FDA approved, the integrase inhibitors, which interfere with the process of integration of complementary viral DNA into the host cell DNA in the nucleus. Also shown are several steps of the replicatory cycle that have yet to be targeted by FDA-approved ARVs.

Citation: Goodkin K, Aronow A, Baldwin G, Molina R, Zheng W, Hardy W. 2009. HIV-1-Associated Neurocognitive Disorders in the HAART Era, p 3-27. In Goodkin K, Shapshak P, Verma A (ed), The Spectrum of Neuro-AIDS Disorders. ASM Press, Washington, DC. doi: 10.1128/9781555815691.ch1
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 2.

Contributory factors to HIV-1-associated neurocognitive-disorder pathogenesis. Studies of HIV-1-associated neurocognitive-disorder pathogenesis have become more complex in the HAART era. Viral and inflammatory/immunologic factors had been the major concerns pre-HAART. In a subset of cases, comorbid infection was also a concern as a contributory factor pre-HAART. A number of additional factors have been identified to be important post-HAART. In particular, a vascular factor is now a routine consideration for pathogenesis. Moreover, newly identified medication toxicity factors (including those due to the ARVs themselves) and host genetic factors have also come to the fore.

Citation: Goodkin K, Aronow A, Baldwin G, Molina R, Zheng W, Hardy W. 2009. HIV-1-Associated Neurocognitive Disorders in the HAART Era, p 3-27. In Goodkin K, Shapshak P, Verma A (ed), The Spectrum of Neuro-AIDS Disorders. ASM Press, Washington, DC. doi: 10.1128/9781555815691.ch1
Permissions and Reprints Request Permissions
Download as Powerpoint


1. Achim, C. L.,, M. P. Heyes, and, C. A. Wiley. 1993. Quantitation of human immunodeficiency virus, immune activation factors, and quinolinic acid in AIDS brains. J. Clin. Investig. 91: 27692775.
2. Alaeus, A.,, K. Lidman,, A. Bjorkman,, J. Giesecke, and, J. Albert. 1999. Similar rate of disease progression among individuals infected with HIV-1 genetic subtypes A–D. AIDS 13: 901907.
3. Alisky, J. M. 2005. Could cholinesterase inhibitors and memantine alleviate HIV dementia? J. Acquir. Immun. Defic. Syndr. 38: 113114. (Letter.)
4. American Academy of Neurology. 1991. Nomenclature and research case definitions for neurological manifestations of human immunodeficiency virus type-1 (HIV-1) infection. Neurology 41: 778785.
5. American Psychiatric Association. 2000. Diagnostic and Statistical Manual of Mental Disorders, 4th ed., text revision. American Psychiatric Association, Washington, DC.
6. Amodio, P.,, E. N. De Toni,, L. Cavalletto,, D. Mapelli,, E. Bernardinello,, F. Del Piccolo,, C. Bergamelli,, R. Costanzo,, F. Bergamaschi,, S. Z. Poma,, L. Chemello,, A. Gatta, and, G. Perini. 2005. Mood, cognition and EEG changes during interferon alpha (alpha-IFN) treatment for chronic hepatitis C. J. Affect. Disord. 84: 9398.
7. Ances, B. M.,, S. Letendre,, M. Buzzell,, J. Marquie-Beck,, D. Lazaretto,, T. D. Marcotte,, I. Grant,, R. J. Ellis, and the HNRC Group. 2006. Valproic acid does not affect markers of human immunodeficiency virus disease progression. J. Neurovirol. 12: 403406.
8. Anthonypillai, C.,, J. E. Gibbs, and, S. A. Thomas. 2006. The distribution of the anti-HIV drug, tenofovir (PMPA), into the brain, CSF and choroid plexuses. Cerebrospinal Fluid Res. 3: 110.
9. Antinori, A.,, G. Arendt,, J. T. Becker,, B. J. Brew,, D. A. Byrd,, M. Cherner,, D. B. Clifford,, P. Cinque,, L. G. Epstein,, K. Goodkin,, M. Gisslen,, I. Grant,, R. K. Heaton,, J. Joseph,, K. Marder,, C. M. Marra,, J. C. McArthur,, M. Nunn,, R. W. Price,, L. Pulliam,, K. R. Robertson,, N. Sacktor,, V. Valcour, and, V. Wojna. 2007. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69: 17891799.
10. Antinori, A.,, C. F. Perno,, M. L. Giancola,, F. Forbici,, G. Ippolito,, R. M. Hoetelmans, and, S. C. Piscitelli. 2005. Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. Clin. Infect. Dis. 41: 17871793.
11. Arici, C.,, D. Ripamonti,, V. Ravasio,, F. Maggiolo,, M. Rizzi,, M. G. Finazzi, and, F. Suter. 2001. Long-term clinical benefit after highly active antiretroviral therapy in advanced HIV-1 infection, even in patients without immune reconstitution. Int. J. STD AIDS 12: 573581.
12. Azini, M.,, S. Nanni,, M. R. Astori,, A. Brunetto, and, L. Massobrio. 1990. Evaluation of neuropsychiatric parameters in HIV positive subjects treated with zidovudine. Acta Neurol. 12: 3639.
13. Baeten, J. M.,, B. Chohan,, L. Lavreys,, V. Chohan,, R. S. McClelland,, L. Certain,, K. Mandaliya,, W. Jaoko, and, J. Overbaugh. 2007. HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J. Infect. Dis. 195: 11771180.
14. Bagetta, G.,, S. Piccirilli,, C. Del Duca,, L. A. Morrone,, L. Rombola,, G. Nappi,, J. De Alba,, R. G. Knowles, and, M. T. Corasaniti. 2004. Inducible nitric oxide synthase is involved in the mechanisms of cocaine enhanced neuronal apoptosis induced by HIV-1 gp120 in the neocortex of rat. Neurosci. Lett. 356: 183186.
15. Baldewicz, T.,, K. Goodkin,, D. J. Feaster,, N. T. Blaney,, M. Kumar,, A. Kumar,, G. Shor-Posner, and, M. Baum. 1998. Plasma pyridoxine deficiency is related to increased psychological distress in recently bereaved homosexual men. Psychosom. Med. 60: 297308.
16. Baldewicz, T. T.,, P. Brouwers,, K. Goodkin,, A. M. Kumar, and, M. Kumar. 2000. Nutritional contributions to the CNS pathophysiology of HIV-1 infection and implications for treatment. CNS Spectr. 5: 6172.
17. Ball, S. C.,, A. Abraha,, K. R. Collins,, A. J. Marozsan,, H. Baird,, M. E. Quinones-Mateu,, A. Penn-Nicholson,, M. Murray,, N. Richard,, M. Lobritz,, P. A. Zimmerman,, T. Kawamura,, A. Blauvelt, and, E. J. Arts. 2003. Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C. J. Virol. 77: 10211038.
18. Barroga, C. F.,, C. Raskino,, M. C. Fangon,, P. E. Palumbo,, C. J. Baker,, J. A. Englund, and, S. A. Spector. 2000. The CCR5Δ32 allele slows disease progression of human immunodeficiency virus-1-infected children receiving antiretroviral treatment. J. Infect. Dis. 182: 413419.
19. Beach, R. S.,, R. Morgan,, F. Wilkie,, E. Mantero-Atienza,, N. Blaney,, G. Shor-Posner,, Y. Lu,, C. Eisdorfer, and, M. K. Baum. 1992. Plasma vitamin B 12 level as a potential cofactor in studies of human immunodeficiency virus type 1-related cognitive changes. Arch. Neurol. 49: 501506.
20. Bell, J. E.,, Y. K. Donaldson,, S. Lowrie,, C. A. McKenzie,, R. A. Elton,, A. Chiswick,, R. P. Brettle,, J. W. Ironside, and, P. Simmonds. 1996. Influence of risk group and zidovudine therapy on the development of HIV encephalitis and cognitive impairment in AIDS patients. AIDS 10: 493499.
21. Berger, J. R.,, J. O. Harris,, J. Gregorios, and, M. Norenberg. 1990. Cerebrovascular disease in AIDS: a case control study. AIDS 4: 239244.
22. Blanch, J.,, E. Martínez,, A. Rousaud,, J.-L. Blanco,, M.-Á. García-Viejo,, J.-M. Peri, et al. 2001. Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz. J. Acquir. Immun. Defic. Syndr. 27: 336343.
23. Breen, E. C.,, A. R. Rezai,, K. Nakajima,, G. N. Beall,, R. T. Mitsuyasu,, T. Hirano,, T. Kishimoto, and, O. Martinez-Maza. 1990. Infection with HIV is associated with elevated IL-6 levels and production. J. Immunol. 144: 480484.
24. Brew, B. J. 2004. Evidence for a change in AIDS dementia complex in the era of highly active antiretroviral therapy and the possibility of new forms of AIDS dementia complex. AIDS 18( Suppl. 1): S75S78.
25. Brew, B. J.,, R. B. Bhalla,, M. Paul,, J. J. Sidtis,, J. J. Keilp,, A. E. Sadler,, H. Gallardo,, J. C. McArthur,, M. K. Schwartz, and, R. W. Price. 1992. Cerebrospinal fluid beta 2-microglobulin in patients with AIDS dementia complex: an expanded series including response to zidovudine treatment. AIDS 6: 461465.
26. Burger, D. M.,, C. L., Kraaijeveld,, P. L. Meenhorst,, J. W. Mulder,, C. H. Koks,, A. Bult, and, J. H. Beijnen. 1993. Penetration of zidovudine into the cerebrospinal fluid of patients infected with HIV. AIDS 7: 15811587.
27. Capini, C. J.,, M. W. Richardson,, H. Hendel,, A. Sverstiuk,, J. Mirchandani,, E. G. Regulier,, K. Khalili,, J. F. Zagury, and, J. Rappaport. 2001. Autoantibodies to TNFα in HIV-1 infection: prospects for anti-cytokine vaccine therapy. Biomed. Pharmacother. 55: 2331.
28. Capparelli, E. V.,, S. L. Letendre,, R. J. Ellis,, P. Patel,, D. Holland, and, J. A. McCutchan. 2005. Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid. Antimicrob. Agents Chemother. 49: 25042506.
29. Carr, A.,, K. Samaras,, A. Thorisdottir,, G. R. Kaufmann,, D. J. Chisholm, and, D. A. Cooper. 1999. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 353: 20932099.
30. Carr, J. M.,, A. J. Davis,, F. Feng,, C. J. Burrell, and, P. Li. 2006. Cellular interactions of virion infectivity factor (Vif) as potential therapeutic targets: APOBEC3G and more? Curr. Drug Targets 7: 15831593.
31. Centers for Disease Control and Prevention. 1986. Classification system for human T-lymphotropic virus type III/lymphadenopathy-associated virus infections. MMWR Morb. Mortal. Wkly. Rep. 35: 3439.
32. Chen, A. M.,, N. Khanna,, S. A. Stohlman, and, C. C. Bergmann. 2005. Virus-specific and bystander CD8 T cells recruited during virus-induced encephalomyelitis. J. Virol. 79: 47004708.
33. Chiesi, A.,, S. Vella,, L. G. Dally,, C. Pedersen,, S. Danner,, A. M. Johnson,, S. Schwander,, F. D. Goebel,, M. Glauser,, F. Antunes, and, J. D. Lundgren for the AIDS in Europe Study Group. 1996. Epidemiology of AIDS dementia complex in Europe. J. Acquir. Immun. Syndr. Hum. Retrovirol. 11: 3944.
34. Chowdhury, M.,, J. P. Taylor,, C. F. Chang,, J. Rappaport, and, K. Khalili. 1992. Evidence that a sequence similar to TAR is important for induction of the JC virus late promoter by human immunodeficiency virus type 1 Tat. J. Virol. 66: 73557361.
35. Clements, J. E.,, M. Li,, L. Gama,, B. Bullock,, L. M. Carruth,, J. L. Mankowski, and, M. C. Zink. 2005. The central nervous system is a viral reservoir in simian immunodeficiency virus-infected macaques on combined antiretroviral therapy: a model for human immunodeficiency virus patients on highly active antiretroviral therapy. J. Neurovirol. 11: 180189.
36. Clifford, D. B.,, S. Evans,, Y. Yang,, E. P. Acosta,, K. Goodkin,, K. Tashima,, D. Simpson,, D. Dorfman,, H. Ribaudo, and, R. M. Gulick for the A5097s Study Team. 2005. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann. Intern. Med. 143: 714721.
37. Clifford, D. B.,, J. C. McArthur,, G. Schifitto,, K. Kieburtz,, M. P. McDermott,, S. Letendre,, B. A. Cohen,, K. Marder,, R. J. Ellis,, C. M. Marra, and the Neurologic AIDS Research Consortium. 2002. A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment. Neurology 59: 15681573.
38. Concha, M.,, S. Symes,, K. Goodkin,, S. Nathan,, P. Zortea,, J. G. Romano,, A. M. Forteza, and, M. Kolber. 2003. Risk of cerebrovascular disease in HIV-1-infected subjects with lipodystrophy syndrome and long-term exposure to protease inhibitors Presented at the 28th International Stroke Conference, Phoenix, AZ, Feb 13–15, 2003, p. 213.
39. Cysique, L. A.,, P. Maruff, and, B. J. Brew. 2006. Valproic acid is associated with cognitive decline in HIV-infected individuals: a clinical observational study. BMC Neurol. 6: 42.
40. Dana Consortium. 1998. A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment. Neurology 50: 645651.
41. Dana Consortium. 1996. Clinical confirmation of the American Academy of Neurology algorithm for HIV-associated cognitive/motor disorder. Neurology 47: 12471253.
42. Digicaylioglu, M.,, M. Kaul,, L. Fletcher,, R. Dowen, and, S. A. Lipton. 2004. Erythropoietin protects cerebrocortical neurons from HIV-1/gp120-induced damage. Neuroreport 15: 761763.
43. Dore, G. J.,, A. McDonald,, Y. Li,, J. M. Kaldor, and, B. J. Brew. 2003. Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 17: 15391545.
44. Ellis, R. J.,, A. C. Gamst,, E. Capparelli,, S. A. Spector,, K. Hsia,, T. Wolfson,, I. Abramson,, I. Grant, and, J. A. McCutchan. 2000. Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources. Neurology 54: 927936.
45. Eugenin, E. A.,, K. Osiecki,, L. Lopez,, H. Goldstein,, T. M. Calderon, and, J. W. Berman. 2006. CCL2/monocyte chemoattractant protein-1 mediates enhanced transmigration of human immunodeficiency virus (HIV)-infected leukocytes across the blood-brain barrier: a potential mechanism of HIV-CNS invasion and neuro-AIDS. J. Neurosci. 26: 10981106.
46. Everall, I. P.,, C. Bell,, M. Mallory,, D. Langford,, A. Adame,, E. Rockestein, and, E. Masliah. 2002. Lithium ameliorates HIV-gp120-mediated neurotoxicity. Mol. Cell. Neurosci 21: 493501.
47. Evers, S.,, D. Nabavi,, A. Rahmann,, C. Heese,, D. Reichelt, and, I. W. Husstedt. 2003. Ischemic cerebrovascular events in HIV infection. Cerebrovasc. Dis. 15: 199205.
48. Fernandez, F.,, F. Adams, and, J. K. Levy. 1988. Cognitive impairment due to AIDS-related complex and its response to psychostimulants Psychosomatics 29: 3846.
49. Ferrando, S.,, W. van Gorp,, M. McElhiney,, K. Goggin,, M. Sewell, and, J. Rabkin. 1998. Highly active antiretroviral treatment in HIV infection: benefits for neuropsychological function. AIDS 12: F65.
50. Fiala, M.,, A. J. Eshleman,, J. Cashman,, J. Lin,, A. S. Lossinsky,, V. Suarez,, W. Yang,, J. Zhang,, W. Popik,, E. Singer,, F. Chiappelli,, E. Carro,, M. Weinand,, M. Witte, and, J. Arthos. 2005. Cocaine increases human immunodeficiency virus type 1 neuroinvasion through remodeling brain microvascular endothelial cells. J. Neurovirol. 11: 281291
51. Fliers, E.,, H. P. Sauerwein,, J. A. Romijn, et al. 2003. HIV-associated adipose redistribution syndrome as a selective autonomic neuropathy. Lancet 362: 17581760.
52. Foster, H. D. 2004. How HIV-1 causes AIDS: implications for prevention and treatment. Med. Hypotheses 62: 549553.
53. Fujimura, R. K.,, I. Khamis,, P. Shapshak, and, K. Goodkin. 2004. Regional quantitative comparison of multispliced to unspliced ratios of HIV-1 RNA copy number in infected human brain. J. Neuro-AIDS 2: 4560.
54. Galgani, S.,, P. Balestra,, P. Narciso,, V. Tozzi,, P. Sette,, F. Pau, and, G. Visco. 1997. Nimodipine plus zidovudine versus zidovudine alone in the treatment of HIV-1-associated cognitive deficits. AIDS 11: 15201521.
55. Gallego, L.,, P. Barreiro,, R. del Río,, D. González de Requena,, A. Rodríguez-Albariño,, J. González-Lahoz, et al. 2004. Analyzing sleep abnormalities in HIV-infected patients treated with efavirenz. Clin. Infect. Dis. 38: 430432.
56. Giancola, M. L.,, P. Lorenzini,, P. Balestra,, D. Larussa,, F. Baldini,, A. Corpolongo,, P. Narciso,, R. Bellagamba,, V. Tozzi, and, A. Antinori. 2006. Neuroactive antiretroviral drugs do not influence neurocognitive performance in less advanced HIV-infected patients responding to highly active antiretroviral therapy. J. Acquir. Immun. Defic. Syndr. 41: 332337.
57. Gisslen, M.,, L. Hagberg,, B. J. Brew,, P. Cinque,, R. W. Price, and, L. Rosengren. 2007. Elevated cerebrospinal fluid neurofilament light protein concentrations predict the development of AIDS dementia complex. J. Infect. Dis. 195: 17741778.
58. Giunta, B.,, D. Obregon,, H. Hou,, J. Zeng,, N. Sun,, V. Nikolic,, J. Ehrhart,, D. Shytle,, F. Fernandez, and, J. Tan. 2006. EGCG mitigates neurotoxicity mediated by HIV-1 proteins gp120 and Tat in the presence of IFN-γ: role of JAK/STAT1 signaling and implications for HIV-associated dementia. Brain Res. 1123: 216225.
59. Gomph, S. 2005. Side effects in interferon and ribavirin therapy for chronic viral hepatitis. e-Med. Hepatitis C Newsl. 2. http://www.emedicine.com/email/hepc/issue2.htm.
60. Gonzalez, E.,, H. Kulkarni,, H. Bolivar,, A. Mangano,, R. Sanchez,, G. Catano,, R. J. Nibbs,, B. I. Freedman,, M. P. Quinones,, M. J. Bamshad,, K. K. Murthy,, B. H. Rovin,, W. Bradley,, R. A. Clark,, S. A. Anderson,, R. J. O’Connell,, B. K. Agan,, S. S. Ahuja,, R. Bologna,, L. Sen,, M. J. Dolan, and, S. K. Ahuja. 2005. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 307: 14341440.
61. Gonzalez, E.,, B. H. Rovin,, L. Sen,, G. Cooke,, R. Dhanda,, S. Mummidi,, H. Kulkarni,, M. J. Bamshad,, V. Telles,, S. A. Anderson,, E. A. Walter,, K. T. Stephan,, M. Deucher,, A. Mangano,, R. Bologna,, S. S. Ahuja,, M. J. Dolan, and, S. K. Ahuja. 2002. HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proc. Natl. Acad. Sci. USA 99: 137795137800.
62. Goodkin, K.,, B. Vitiello,, W. D. Lyman,, D. Asthana,, J. H. Atkinson,, P. N. R. Heseltine,, R. Molina,, W. Zheng,, I. Khamis,, F. L. Wilkie, and, P. Shapshak. 2006. Cerebrospinal and peripheral human immunodeficiency virus type1 load in a multi-site, randomized, double blind, placebo-controlled trial of d-ala1-peptide T-amide for associated cognitive-motor impairment. J. Neurovirol. 12: 178189.
63. Goodkin, K.,, F. L. Wilkie,, T. T. Baldewicz,, M. Concha,, M. D. Tyll,, C. J. LoPiccolo, and, P. Shapshak. 2000. HIV-1 associated cognitive-motor disorders: a research-based approach to diagnosis and treatment. CNS Spectr. 5: 4960.
64. Goodkin, K.,, F. L. Wilkie,, M. Concha,, C. H. Hinkin,, S. Symes,, T. T. Baldewicz,, D. Asthana,, R. K. Fujimura,, D. Lee,, M. H. van Zuilen,, I. Khamis,, P. Shapshak, and, C. Eisdorfer. 2001. Aging and neuro-AIDS conditions: a potential interaction with the changing spectrum of HIV-1 associated morbidity and mortality in the era of HAART? J. Clin. Epidemiol. 54( Suppl. 1): S35S43.
65. Gray, F.,, H. Adle-Biassette,, F. Chretien,, G. Lorin de la Grandmaison,, G. Force, and, C. Keohane. 2001. Neuropathology and neurodegeneration in human immunodeficiency virus infection. Clin. Neuropathol. 20: 146155.
66. Grigem, S.,, P. Fischer-Posovszky,, K. M. Debatin,, E. Loizon,, H. Vidal, and, M. Wabitsch. 2005. The effect of the HIV protease inhibitor ritonavir on proliferation, differentiation, lipogenesis, gene expression and apoptosis of human preadipocytes and adipocytes. Horm. Metab. Res. 37: 602609.
67. Grimwade, K.,, N. French,, D. D. Mbatha,, D. D. Zungu,, M. Dedicoat, and, C. F. Gilks. 2004. HIV infection as a cofactor for severe falciparum malaria in adults living in a region of unstable malaria transmission in South Africa. AIDS 18: 547554.
68. Henderson, D. C.,, E. Cagliero,, P. M. Copeland,, C. P. Borba,, E. Evins,, D. Hayden,, M. T. Weber,, E. J. Anderson,, D. B. Allison,, T. B. Daley,, D. Schoenfeld, and, D. C. Goff. 2005. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled glucose tolerance test and minimal model analysis. Arch. Gen. Psychiatry 62: 1928.
69. Henry, K.,, H. Melroe,, J. Huebsch,, J. Hermundson,, C. Levine,, L. Swensen, and, J. Daly. 1998. Severe premature coronary artery disease with protease inhibitors. Lancet 351: 1328.
70. Herzlich, B. C.,, and T. D. Schiano. 1993. Reversal of apparent AIDS dementia complex following treatment with vitamin B 12. J. Int. Med. 233: 495497.
71. Heseltine, P. N. R.,, K. Goodkin,, J. H. Atkinson,, B. Vitiello,, J. Rochon,, R. K. Heaton,, E. Eaton,, F. Wilkie,, E. Sobel,, S. Brown,, D. Feaster,, L. Schneider,, E. Stover, and, S. H. Koslow. 1998. Randomized, double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment. Arch. Neurol. 55: 4151.
72. Heyes, M. P.,, K. Saito, and, S. P. Markey. 1992. Human macrophages convert l-tryptophan into the neurotoxin quinolinic acid. J. Biochem. 83: 633635.
73. Hinkin, C. H.,, S. A. Castellon,, D. J. Hardy,, R. Farinpour,, T. Newton, and, E. Singer. 2001. Methylphenidate improves HIV-1-associated cognitive slowing. J. Neuropsychiatry Clin. Neurosci. 13: 248254.
74. Ho, W.,, J. Harouse,, R. Rando,, E. Gonczol,, A. Srinivasan, and, S. Plotkin. 1990. Reciprocal enhancement of gene expression and viral replication between human cytomegalovirus and human immunodeficiency virus-1. J. Gen. Virol. 71: 97103.
75. Jaworowski, A.,, D. D. Kamwendo,, P. Ellery,, S. Sonza,, V. Mwapasa,, E. Tadesse,, M. E. Molyneux,, S. J. Rogerson,, S. R. Meshnick, and, S. M. Crowe. 2007. CD16 + monocyte subset preferentially harbors HIV-1 and is expanded in pregnant Malawian women with Plasmodium falciparum malaria and HIV-1 infection. J. Infect. Dis. 196: 3842.
76. Kaul, M.,, and S. A. Lipton. 1999. Chemokines and activated macrophages in HIV gp120-induced neuronal apoptosis. Proc. Natl. Acad. Sci. USA 96: 82128216.
77. Kelder, W.,, J. C. McArthur,, T. Nance-Sproson,, D. McClernon, and, D. E. Griffin. 1998. Beta-chemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-associated dementia. Ann. Neurol. 44: 831835.
78. Khan, N. A.,, F. Di Cello,, A. Nath, and, K. S. Kim. 2003. Human immunodeficiency virus type 1 tat-mediated cytotoxicity of human brain microvascular endothelial cells. J. Neurovirol. 9: 584593.
79. Kieburtz, K. D.,, L. G. Epstein,, H. A. Gelbard, and, J. T. Greenamyre. 1991. Excitotoxicity and dopaminergic dysfunction in the acquired immunodeficiency syndrome dementia complex. Arch. Neurol. 48: 12811284.
80. Kilic, U.,, E. Kilic,, G. P. Dietz, and, M. Bahr. 2003. Intravenous TAT-GDNF is protective after focal cerebral ischemia in mice. Stroke 34: 13041310.
81. Klein, M. B.,, R. G. Lalonde, and, S. Suissa. 2003. The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy. J. Acquir. Immun. Defic. Syndr. 33: 365372.
82. Koutsilieri, E.,, S. Czub,, C. Scheller,, S. Sopper,, T. Tatschner,, C. Stahl-Hennig,, V. ter Meulen, and, P. Riederer. 2000. Brain choline acetyltransferase reduction in SIV infection. An index of early dementia? Neuroreport 11: 23912393.
83. Kumar, A. M.,, J. R. Berger,, C. Eisdorfer,, J. B. Fernandez,, K. Goodkin, and, M. Kumar. 2001. Cerebrospinal fluid 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in HIV-1 infection. Neuropsychobiology 44: 1318.
84. Lanjewar, D. N.,, P. P. Jain, and, C. R. Shetty. 1998. Profile of central nervous system pathology in patients with AIDS: an autopsy study from India. AIDS 12: 309313.
85. Larder, B. A.,, G. Darby, and, D. D. Richman. 1989. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243: 17311734.
86. Larsson, M.,, L. Hagberg,, A. Forsman, and, G. Norkrans. 1991. Cerebrospinal fluid catecholamine metabolites in HIV-infected patients. J. Neurosci. Res. 28: 406409.
87. Le Buanec, H.,, A. Lachgar,, B. Bizzini,, J. F. Zagury,, J. Rappaport,, E. Santagostino,, M. Muca-Perja, and, A. Gringeri. 1998. A prophylactic and therapeutic AIDS vaccine containing as a component the innocuous Tat toxoid. Biomed. Pharmacother. 52: 431435.
88. Lemoine, M.,, V. Barbu,, P. M. Girard,, M. Kim,, J. P. Bastard,, D. Wendum,, F. Paye,, C. Housset,, J. Capeau, and, L. Serfaty. 2006. Altered hepatic expression of SREBP-1 and PPARγ is associated with liver injury in insulin-resistant lipodystrophic HIV-infected patients. AIDS 20: 387395.
89. LeTendre, S.,, B. Ances,, S. Gibson, and, R. J. Ellis. 2007. Neurologic complications of HIV disease and their treatment. Topics HIV Med. 15: 3239.
90. LeTendre, S. L.,, S. P. Woods,, R. J. Ellis,, J. H. Atkinson,, E. Masliah,, G. van den Brande,, J. Durelle,, I. Grant,, I. Everall, and the HNRC Group. 2006. Lithium improves HIV-associated neurocognitive impairment. AIDS 20: 18851888.
91. LeTendre, S. L.,, E. R. Lanier, and, J. A. McCutchan. 1999. Cerebrospinal fluid beta chemokine concentrations in neurocognitively impaired individuals infected with human immunodeficiency virus type 1. J. Infect. Dis. 180: 310319.
92. Lichtenstein, K. A.,, K. M. Delaney,, C. Armon,, D. J. Ward,, A. C. Mourman,, K. C. Wood,, S. D. Holmberg, and HIV Outpatient Study Investigators. 2003. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J. AIDS 32: 4856.
93. Lieb, K.,, M. A. Engelbrecht,, O. Gut,, B. L. Fiebich,, J. Bauer,, G. Janssen, and, M. Schaefer. 2006. Cognitive impairment in patients with chronic hepatitis treated with interferon alpha (IFNα): results from a prospective study. Eur. Psychiatry 21: 204210.
94. Lochet, P.,, H. Peyriere,, A. Lotthé,, J. M. Mauboussin,, B. Delmas, and, J. Reynes. 2003. Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med. 4: 6266.
95. Madruga, J. V.,, P. Cahn,, B. Grinsztejn,, R. Haubrich,, J. Lalezari,, A. Mills,, G. Pialoux,, T. Wilkin,, M. Peeters,, J. Vingerhoets,, G. de Smedt,, L. Leopold,, R. Trefiglio,, B. Woodfall, and the DUET-1 Study Group. 2007. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 370: 2938.
96. Maggirwar, S. B.,, N. Tong,, S. Ramirez,, H. A. Gelbard, and, S. Dewhurst. 1999. HIV-1 Tat-mediated activation of glycogen synthase kinase-3β contributes to Tat-mediated neurotoxicity. J. Neurochem. 73: 578586.
97. Mana, P.,, D. Linares,, S. Fordham,, M. Staykova, and, D. Willenborg. 2006. Deleterious role of IFNγ in a toxic model of central nervous system demyelination. Am. J. Pathol. 168: 14641473.
98. Martin, C.,, A. Sonnerborg,, J. O. Svensson, and, L. Stahle. 1999. Indinavir-based treatment of HIV-1 infected patients: Efficacy in the central nervous system. AIDS 13: 12271232.
99. McArthur, J. C.,, D. R. McClernon,, M. F. Cronin,, T. E. Nance-Sproson,, A. J. Saah,, M. St Clair, and, E. R. Lanier. 1997. Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann. Neurol. 42: 689698.
100. McArthur, J. C.,, D. R. Hoover,, H. Bacellar,, E. N. Miller,, B. A. Cohen,, J. T. Becker,, N. M. Graham,, J. H. McArthur,, O. A. Selnes,, L. P. Jacobson,, B. R. Visscher,, M. Concha, and, A. Saah. 1993. Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology 43: 22452252.
101. McDowell, J. A.,, G. E. Chittick,, J. R. Ravitch,, R. E. Polk,, T. M. Kerkering, and, D. S. Stein. 1999. Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study. Antimicrob. Agents. Chemother. 43: 28552861.
102. McNair, D. M.,, M. Lorr, and, L. F. Droppleman. 1971. Profile of Mood States Manual. Educational Industrial Testing Service, San Diego, CA.
103. Mellgren, A.,, R. W. Price,, L. Hagberg,, L. Rosengren,, B. J. Brew, and, M. Gisslen. 2007. Antiretroviral treatment reduces increased CSF neurofilament protein (NFL) in HIV-1 infection. Neurology 69: 15361541.
104. Miller, R. F.,, P. G. Isaacson,, M. Hall-Craggs,, S. Lucas,, F. Gray,, F. Scaravilli, and, S. F. An. 2004. Cerebral CD8 + lymphocytosis in HIV-1 infected patients with immune restoration induced by HAART. Acta Neuropathol. 108: 1723.
105. Mohsen, A. H.,, P. J. Easterbrook,, C. Taylor,, B. Portmann,, R. Kulasegaram,, S. Murad,, M. Wiselka, and, S. Norris. 2003. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut 52: 10351040.
106. Moog, C.,, G. Kuntz-Simon,, C. Caussin-Schwemling, and, G. Obert. 1996. Sodium valproate, an anticonvulsant drug, stimulates human immunodeficiency virus type 1 replication independently of glutathione levels. J. Gen. Virol. 77: 19931999.
107. Moyle, G. 2005. A review of the aetiology of dyslipidaemia and hyperlipidaemia in patients with HIV. Int. J. STD AIDS 16( Suppl. 1): 1422.
108. Mulligan, K.,, Y. Yang,, D. A. Wininger,, S. L. Koletar,, R. A. Parker,, B. L. Alston-Smith,, J. T. Schouten,, R. A. Fielding,, M. T. Basar, and, S. Grinspoon. 2007. Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio. AIDS 21: 4757.
109. Nance, C. L.,, and W. T. Shearer. 2003. Is green tea good for HIV-1 infection? J. Allergy Clin. Immunol. 112: 851853.
110. Navia, B. A.,, U. Dafni,, D. Simpson,, T. Tucker,, E. Singer,, J. C. McArthur,, C. Yiannoutsos,, L. Zaborski, and, S. A. Lipton. 1998. A phase I/II trial of nimodipine for HIV-related complications. Neurology 51: 221228.
111. Navia, B. A.,, B. D Jordan, and, R. W. Price. 1986a. The AIDS dementia complex. I. Clinical features. Ann. Neurol. 91: 517524.
112. Navia, B. A.,, E.-S. Cho,, C. K. Petito, and, R. W. Price. 1986b. The AIDS dementia complex. II. Neuropathology. Ann. Neurol. 91: 525535.
113. Neuenburg, J. K.,, H. R. Brodt,, B. G. Herndier,, M. Bickel,, P. Bacchetti,, R. W. Price,, R. M. Grant, and, W. Schlote. 2002. HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J. Acquir. Immun. Defic. Syndr. 31: 171177.
114. Nosheny, R. L.,, A. Bachis,, S. A. Aden,, M. A. De Bernardi, and, I. Mocchetti. 2006. Intrastriatal administration of human immunodeficiency virus-1 glycoprotein 120 reduces glial cell-line derived neurotrophic factor levels and causes apoptosis in the substantia nigra. J. Neurobiol. 66: 13111321.
115. Osborn, L.,, S. Kunkel, and, G. J. Nabel. 1989. Tumor necrosis factor alpha and interleukin-1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor KB. Proc. Natl. Acad. Sci. USA 86: 23362340.
116. Pavol, M. A.,, C. A. Meyers,, J. L. Rexer,, A. D. Valentine,, P. J. Mattis, and, M. Talpaz. 1995. Pattern of neurobehavioral deficits with interferon alpha therapy for leukemia. Neurology 45: 947950.
117. Pereira, C. F.,, J. Middel,, G. Jansen,, J. Verhoef, and, H. S. Nottet. 2001. Enhanced expression of fractalkine in HIV-1 associated dementia. J. Neuroimmunol. 115: 168175.
118. Petito, C. K.,, J. E. Torres-Munoz,, F. Zielger, and, M. McCarthy. 2006. Brain CD8 + and cytotoxic T lymphocytes are associated with, and may be specific for, human immunodeficiency virus type 1 encephalitis in patients with acquired immunodeficiency syndrome. J. Neurovirol. 12: 272283.
119. Petito, C. K.,, B. Adkins,, M. McCarthy, and, B. Roberts. 2003. Khamis I. CD4 + and CD8 + cells accumulate in the brains of acquired immunodeficiency syndrome patients with human immunodeficiency virus encephalitis. J. Neurovirol. 9: 3644.
120. Petito, C. K.,, and B. Roberts. 1995. Evidence of apoptotic cell death in HIV encephalitis. Am. J. Pathol. 146: 11211130.
121. Popko, B.,, J. G. Corbin,, K. D. Baerwald,, J. Dupree, and, A. M. Garcia. 1997. The effects of interferon-gamma on the central nervous system. Mol.c Neurobiol. 14: 1935.
122. Poulter, M. O.,, K. B. Payne, and, J. P. Steiner. 2004. Neuroimmunophilins: a novel drug therapy for the reversal of neurodegenerative disease? Neuroscience 128: 16.
123. Poutiainen, E.,, L. Hokkanen,, M. L. Niemi, and, M. Farkkila. 1994. Reversible cognitive decline during high-dose alpha-inter-feron treatment. Pharmacol. Biochem. Behavior 47: 901905.
124. Pumfery, A.,, C. de la Fuente,, R. Berro,, S. Nekhai,, F. Kashanchi, and, S. H. Chao. 2006. Potential use of pharmacological cyclin-dependent kinase inhibitors as anti-HIV therapeutics. Curr. Pharm. Des. 12: 19491961.
125. Ranga, U.,, R. Shankarappa,, N. B. Siddappa,, L. Ramakrishna,, R. Nagendran,, M. Mahalingam,, A. Mahadevan,, N. Jayasuryan,, P. Satishchandra,, S. K. Shankar, and, V. R. Prasad. 2004. Tat protein of human immunodeficiency virus type 1 subtype C strains is a defective chemokine. J. Virol. 78: 25862590.
126. Ricardo-Dukelow, M.,, I. Kadiu,, W. Rozek,, J. Schlautman,, Y. Persidsky,, P. Ciborowski,, G. D. Kanmogne, and, H. E. Gendelman. 2007. HIV-1 infected monocyte-derived macrophages affect the human brain microvascular endothelial cell proteome: new insights into blood-brain barrier dysfunction for HIV-1-associated dementia. J. Neuroimmunol. 185: 3746.
127. Robertson, K. R.,, M. Smurzynski,, T. D. Parsons,, K. Wu,, R. J. Bosch,, J. Wu,, J. C. McArthur,, A. C. Collier,, S. R. Evans, and, R. J. Ellis. 2007. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 21: 19151921.
128. Ruff, M. R.,, L. M. Melendez-Guerrero,, Q. E. Yang,, W. Z. Ho,, J. W. Mikovits,, C. B. Pert, and, F. A. Ruscetti. 2001. Peptide T inhibits HIV-1 infection mediated by the chemokine receptor-5 (CCR5). Antivir. Res. 52: 6375.
129. Saavedra-Lozano, J.,, J. T. Ramos,, F. Sanz,, M. L. Navarro,, M. I. de Jose,, P. Martin-Fontelos,, M. J. Mellado,, J. A. Leal,, C. Rodriguez,, I. Luque,, S. J. Madison,, D. Irlbeck,, E. R. Lanier, and, O. Ramilo. 2006. Salvage therapy with abacavir and other reverse transcriptase inhibitors for human immunodeficiency-associated encephalopathy. Pediatr. Infect. Dis. J. 25: 11421152.
130. Sabri, F.,, A. De Milito,, R. Pirskanen,, I. Elovaara,, L. Hagberg,, P. Cinque,, R. Price, and, F. Chiodi. 2001. Elevated levels of soluble Fas and Fas ligand in cerebrospinal fluid of patients with AIDS dementia complex. J. Neuroimmunol. 114: 197206.
131. Sacktor, N.,, M. P. McDermott,, K. Marder,, G. Schifitto,, O. A. Selnes,, J. C. McArthur,, Y. Stern,, S. Albert,, D. Palumbo,, K. Kieburtz,, J. A. De Marcaida,, B. Cohen, and, L. Epstein. 2002. HIV-associated cognitive impairment before and after the advent of combination therapy. J. Neurovirol. 8: 136142.
132. Sacktor, N.,, R. H. Lyles,, R. Skolasky,, C. Kleeberger,, O. A. Selnes,, E. N. Miller,, J. T. Becker,, B. Cohen, and, J. C. McArthur. 2001. HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990–1998. Neurology 56: 257260.
133. Sacktor, N.,, G. Schifitto,, M. P. McDermott,, K. Marder,, J. C. McArthur, and, K. Kieburtz. 2000. Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study. Neurology 54: 233235.
134. Sacktor, N. C.,, R. H. Lyles,, R. L. Skolasky,, D. E. Anderson,, J. C. McArthur,, G. McFarlane,, O. A. Selnes,, J. T. Becker,, B. Cohen,, J. Wesch, and, E. N. Miller. 1999. Combination antiretroviral therapy improves psychomotor speed performance in HIV-seropositive homosexual men. Neurology 52: 16401647.
135. Sardar, A. M.,, C. Czudek, and, G. P. Reynolds. 1996. Dopamine deficits in the brain: the neurochemical basis of parkinsonian symptoms in AIDS. Neuroreport 7: 910912.
136. Sas, A. R.,, H. A. Bimonte-Nelson, and, W. R. Tyor. 2007. Cognitive dysfunction in HIV encephalitic SCID mice correlates with levels of interferon-alpha in the brain. AIDS 21: 21512159.
137. Sax, P. E.,, R. Islam,, R. P. Walensky,, E. Losina,, M. C. Weinstein,, S. J. Goldie,, S. N. Sadownik, and, K. A. Freedberg. 2005. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin. Infect. Dis. 41: 13161323.
138. Schifitto, G.,, B. A. Navia,, C. T. Yiannoutsos,, C. M. Marra,, L. Chang,, T. Ernst,, J. G. Jarvik,, E. N. Miller,, E. J. Singer,, R. J. Ellis,, D. L. Kolson,, D. Simpson,, A. Nath,, J. Berger,, S. L. Shriver,, L. L. Millar,, D. Colquhoun,, R. Lenkinski,, R. G. Gonzalez,, S. A. Lipton, and the Adult AIDS Clinical Trial Group (ACTG) 301, 700 Teams, and the HIV MRS Consortium. 2007. Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS 21: 18771886.
139. Schifitto, G.,, D. R. Peterson,, J. Zhong,, H. Ni,, K. Cruttenden,, M. Gaugh,, H. E. Gendelman,, M. Boska, and, H. Gelbard. 2006. Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report. Neurology 66: 919921.
140. Schifitto, G.,, N. Sacktor,, K. Marder,, M. P. McDermott,, J. C. McArthur,, K. Kieburtz,, S. Small, and, L. G. Epstein. 1999. Randomized trial of the platelet-activating factor antagonist lexipafant in HIV-associated cognitive impairment. Neurology 53: 391396.
141. Schmitt, F. A.,, J. W. Bigley,, R. McKinnis,, P. E. Logue,, R. W. Evans, and, J. L. Drucker. 1988. Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. N. Engl. J. Med. 319: 15731578.
142. Sevigny, J. J.,, S. M. Albert,, M. P. McDermott,, J. C. McArthur,, N. Sacktor,, K. Conant,, G. Schifitto,, O. A. Selnes,, Y. Stern,, D. R. McClernon,, D. Palumbo,, K. Kieburtz,, G. Riggs,, B. Cohen,, L. G. Epstein, and, K. Marder. 2004. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology 63: 20842090.
143. Shapshak, P.,, S. M. Segal,, K. A. Crandall,, R. K. Fujimura,, B.-T. Zhang,, K.-Q. Xin,, K. Okuda,, C. K. Petito,, C. Eisdorfer, and, K. Goodkin. 1999. Independent evolution of HIV type 1 in different brain regions. AIDS Res. Hum. Retrovir. 15: 811820.
144. Sibson, N. R.,, A. M. Blamire,, V. H. Perry,, J. Gauldie,, P. Styles, and, D. C. Anthony. 2002. TNF-alpha reduces cerebral blood volume and disrupts tissue homeostasis via an endothelin- and TNFR2-dependent pathway. Brain 125: 24462459.
145. Sidtis, J. J.,, C. Gatsonis,, R. W. Price,, E. J. Singer,, A. C. Collier,, D. D. Richman,, M. S. Hirsch,, F. W. Schaerf,, M. A. Fischl,, K. Kieburtz, et al. 1993. Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. Ann. Neurol. 33: 343349.
146. Singh, D.,, and K. Goodkin. 2007a. Choice of antipsychotic medications in HIV-infected patients. J. Clin. Psychiatry 68: 479480.
147. Singh, D.,, and K. Goodkin. 2007b. Psychopharmacologic treatment responses of HIV-infected patients to antipsychotic medications. J. Clin. Psychiatry 68: 631632.
148. Snider, W. D.,, D. M. Simpson,, S. Nielsen,, J. W. Gold,, C. E. Metroka, and, J. B. Posner. 1983. Neurological complications of acquired immune deficiency syndrome: analysis of 50 patients. Ann. Neurol. 14: 403418.
149. Stahle, L.,, C. Martin,, J. O. Svensson, and, A. Sonnerborg. 1997. Indinavir in cerebrospinal fluid of HIV-1 infected patients. Lancet 350: 1823.
150. Stankov, M. V.,, T. Lucke,, A. M. Das,, R. E. Schmidt, and, G. M. Behrens. 2007. Relationship of mitochondrial DNA depletion and respiratory chain activity in preadipocytes treated with nucleoside reverse transcriptase inhibitors. Antivir. Ther. 12: 205216.
151. Stephens, E. B.,, S. V. Joag,, B. Atkinson,, M. Sahni,, Z. Li,, L. Foresman,, I. Adany, and, O. Narayan. 1997. Infected macaques that controlled replication of SIVmac or nonpathogenic SHIV developed sterilizing resistance against pathogenic SHIV(KU-1). Virology 234: 328339.
152. Stephensen, C. B.,, G. S. Marquis,, S. D. Douglas,, L. A. Kruzich, and, C. M. Wilson. 2007. Glutathione, glutathione peroxidase, and selenium status in HIV-positive and HIV-negative adolescents and young adults. Am. J. Clin. Nutr. 85: 173181.
153. Tan, B.,, D. Piwnica-Worms, and, L. Ratner. 2000. Multidrug resistance transporters and modulation. Curr. Opin. Oncol. 12: 450458.
154. Tashima, K. T.,, A. M. Caliendo,, M. Ahmad,, J. M. Gormley,, W. D. Fiske,, J. M. Brennan, and, T. P. Flanigan. 1999. Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy. J. Infect. Dis. 180: 862864.
155. Theodore, S.,, W. A. Cass,, A. Nath,, J. Steiner,, K. Young, and, W. F. Maragos. 2006. Inhibition of tumor necrosis factor-alpha signaling prevents human immunodeficiency virus-1 protein Tat and methamphetamine interaction. Neurobiol. Dis. 23: 663668.
156. Thomas, S. A.,, and M. B. Segal. 1998. The transport of the anti-HIV drug 2′,3′-didehydro-3′-deoxythymidine (d4T) across the blood-brain and blood-cerebrospinal fluid barriers. Br. J. Pharmacol. 125: 4954.
157. Thornton, C. A.,, S. Houston, and, A. S. Latif. 1992. Neurocysticercosis and human immunodeficiency virus infection. A possible association. Arch. Neurol. 49: 963965.
158. Toborek, M.,, Y. W. Lee,, G. Flora,, H. Pu,, I. E. Andras,, E. Wylegala,, B. Hennig, and, A. Nath. 2005. Mechanisms of the blood-brain barrier disruption in HIV-1 infection. Cell. Mol. Neurobiol. 25: 181199.
159. Tomac, A.,, E. Lindqvist,, L.-F. H. Lin,, S. O. Ogren,, D. Young,, B. J. Hoffer, and, L. Olson. 1995. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373: 335339.
160. Tong, N.,, J. F. Sanchez,, S. B. Maggirwar,, S. H. Ramirez,, H. Guo,, S. Dewhurst, and, H. A. Gelbard. 2001. Activation of glycogen synthase kinase 3 beta (GSK-3β) by platelet activating factor mediates migration and cell death in cerebellar granule neurons. Eur. J. Neurosci. 13: 19131922.
161. Toossi, Z.,, H. Mayanja-Kizza,, S. D. Lawn,, C. S. Hirsch,, L. D. Lupo, and, S. T. Butera. 2007. Dynamic variation in the cellular origin of HIV type 1 during treatment of tuberculosis in dually infected subjects. AIDS Res. Hum. Retrovir. 23: 93100.
162. Tozzi, V.,, P. Balestra,, S. Galgani,, P. Narciso,, A. Sampaolesi,, A. Antinori,, M. Giulianelli,, D. Serraino, and, G. Ippolito. 2001. Changes in neurocognitive performance in a cohort of patients treated with HAART for 3 years. J. Acquir. Immun. Defic. Syndr. 28: 1927.
163. Tyor, W. R.,, and L. D. Middaugh. 1999. Do alcohol and cocaine abuse alter the course of HIV-associated dementia complex? J. Leukoc. Biol. 65: 475481.
164. Vago, L.,, A. Castagna,, A. Lazzarin,, G. Trabattoni,, P. Cinque, and, G. Costanzi. 1993. Reduced frequency of HIV-induced brain lesions in AIDS patients treated with zidovudine. J. Acquir. Immun. Defic. Syndr. 6: 4245.
165. Valcour, V.,, C. Shikuma,, B. Shiramizu,, M. Watters,, P. Poff,, O. Selnes,, P. Holck,, J. Grove, and, N. Sacktor. 2004. Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort. Neurology 63: 822827.
166. Valcour, V. G.,, C. M. Shikuma,, B. T. Shiramizu,, A. E. Williams,, M. R. Watters,, P. W. Poff,, J. S. Grove,, O. A. Selnes, and, N. C. Sacktor. 2005. Diabetes, insulin resistance, and dementia among HIV-1-infected patients. J. Acquir. Immun. Defic. Syndr. 38: 3136.
167. van Asten, L.,, and M. Prins. 2004. Infection with concurrent multiple hepatitis C virus genotypes is associated with faster HIV disease progression. AIDS 18: 23192324.
168. van der Meer, P.,, A. M. Ulrich,, F. Gonalez-Scarano, and, E. Lavi. 2000. Immunohistochemical analysis of CCR2, CCR3, CCR5, and CXCR4 in the human brain: potential mechanisms for HIV dementia. Exp. Mol. Pathol. 69: 192201.
169. van Dyck, C. H.,, T. J. McMahon,, M. I. Rosen,, S. S. O’Malley,, P. G. O’Connor,, C. H. Lin,, H. R. Pearsall,, S. W. Woods, and, T. R. Kosten. 1997. Sustained-release methylphenidate for cognitive impairment in HIV-1-infected drug abusers: a pilot study. J. Neuropsychiatry Clin. Neurosci. 9: 2936.
170. Vazeux, R.,, M. Cumont,, P. M. Girard,, X. Nassif,, P. Trotot,, C. Marche,, L. Matthiessen,, C. Vedrenne,, J. Mikol,, D. Henin, et al. 1990. Severe encephalitis resulting from coin-fections with HIV and JC virus. Neurology 40: 944948.
171. Vendrely, A.,, B. Bienvenu,, J. Gasnault,, J. B. Thiebault,, D. Salmon, and, F. Gray. 2005. Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy. Acta Neuropathol. 109: 449455.
172. Vergote, D.,, G. S. Butler,, M. Ooms,, J. H. Cox,, C. Silva,, M. D. Hollenberg,, J. H. Jhamandas,, C. M. Overall, and, C. Power. 2006. Proteolytic processing of SDF-1α reveals a change in receptor specificity mediating HIV-associated neurodegeneration. Proc. Natl. Acad. Sci. USA 103: 1918219187.
173. Vigouroux, C.,, S. Gharakhanian,, Y. Salhi, et al. 1999. Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART). Diabetes Metab. 25: 225232.
174. Wachtman, L. M.,, R. L. Skolasky,, P. M. Tarwater,, D. Esposito,, G. Schifitto,, K. Marder,, M. P. McDermott,, B. A. Cohen,, A. Nath,, N. Sacktor,, L. G. Epstein,, J. L. Mankowski, and, J. C. McArthur. 2007. Platelet decline: an avenue for investigation into the pathogenesis of human immunodeficiency virus-associated dementia. Arch. Neurol. 64: 12641272.
175. Wesselingh, S.,, C. Power,, J. Glass, et al. 1993. Intracerebral cytokine mRNA expression in AIDS dementia. Ann. Neurol. 33: 576582.
176. Westmoreland, S. V.,, D. Kolson, and, F. Gonzalez-Scarano. 1996. Toxicity of TNF alpha and platelet activating factor for human NT2N neurons: a tissue culture model for human immunodeficiency virus dementia. J. Neurovirol. 2: 118126.
177. Wilkinson, I. D.,, W. K. Chong,, M. Paley,, J. K. Shepherd,, R. J. S. Chinn,, R. F. Miller,, B. Sweeney,, B. E. Kendall,, M. A. Hall-Craggs, and, M. J. G. Harrison. 1996. Blood-brain barrier integrity in HIV infection: Evaluation by contrast-enhanced magnetic resonance imaging. J. Neuro-AIDS 1: 1731.
178. Wilt, S. G.,, E. Milward,, J. M. Zhou,, K. Nagasato,, H. Patton,, R. Rusten,, D. E. Griffin,, M. O’Connor, and, M. Dubois-Dalcq. 1995. In vitro evidence for a dual role of tumor necrosis factor-α in human immunodeficiency virus type 1 encephalopathy. Ann. Neurol. 37: 381394.
179. Wohl, D. A.,, D. Zeng,, P. Stewart,, N. Glomb,, T. Alcorn,, S. Jones,, J. Handy,, S. Fiscus,, A. Weinberg,, D. Gowda, and, C. van der Horst. 2005. Cytomegalovirus viremia, mortality, and end-organ disease among patients with AIDS receiving potent antiretroviral therapies. J. Acquir. Immun. Defic. Syndr. 38: 538544.
180. Yarchoan, R.,, J. M. Pluda,, R. V. Thomas, et al. 1990. Long-term toxicity/activity profile of 2′,3′-dideoxyinosine in AIDS or AIDS-related complex. Lancet 336: 526529.
181. Yepthomi, T.,, R. Paul,, S. Vallabhaneni,, N. Kumarasamy,, D. F. Tate,, S. Solomon, and, T. Flanigan. 2006. Neurocognitive consequences of HIV in southern India: a preliminary study of clade C virus. J. Int. Neuropsych. Soc. 12: 424430.
182. Zelman, I. B.,, and M. J. Mossakowski. 1998. Opportunistic infections of the central nervous system in the course of acquired immune deficiency syndrome (AIDS). Morphological analysis of 172 cases. Folia Neuropathol. 36: 129144.
183. Zhu, T.,, H. Mo,, N. Wang,, D. S. Nam,, Y. Cao,, R. A. Koup, and, D. D. Ho. 1993. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 261: 11791181.
184. Zink, M. C.,, J. Uhrlaub,, J. DeWitt,, T. Voelker,, B. Bullock,, J. Mankowski,, P. Tarwater,, J. Clements, and, S. Barber. 2005. Neuroprotective and anti-human immunodeficiency virus activity of minocycline. JAMA 293: 20032011.


Generic image for table

The changing manifestations of HAD pre- and post-HAART

Citation: Goodkin K, Aronow A, Baldwin G, Molina R, Zheng W, Hardy W. 2009. HIV-1-Associated Neurocognitive Disorders in the HAART Era, p 3-27. In Goodkin K, Shapshak P, Verma A (ed), The Spectrum of Neuro-AIDS Disorders. ASM Press, Washington, DC. doi: 10.1128/9781555815691.ch1
Generic image for table

Role of cytokines in the pathogenesis of HIV-1-associated neurocognitive impairment and disorder

Citation: Goodkin K, Aronow A, Baldwin G, Molina R, Zheng W, Hardy W. 2009. HIV-1-Associated Neurocognitive Disorders in the HAART Era, p 3-27. In Goodkin K, Shapshak P, Verma A (ed), The Spectrum of Neuro-AIDS Disorders. ASM Press, Washington, DC. doi: 10.1128/9781555815691.ch1

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error